U.S. Markets closed
  • S&P 500

    -5.76 (-0.16%)
  • Dow 30

    -173.77 (-0.58%)
  • Nasdaq

    +57.62 (+0.48%)
  • Russell 2000

    -8.51 (-0.46%)
  • Crude Oil

    -0.77 (-1.68%)
  • Gold

    +2.40 (+0.13%)
  • Silver

    -0.05 (-0.22%)

    -0.0007 (-0.0596%)
  • 10-Yr Bond

    -0.0040 (-0.45%)
  • Vix

    -0.39 (-1.80%)

    -0.0032 (-0.2403%)

    -0.1840 (-0.1762%)

    -1,276.43 (-7.10%)
  • CMC Crypto 200

    -44.10 (-11.90%)
  • FTSE 100

    -28.16 (-0.44%)
  • Nikkei 225

    +240.45 (+0.91%)

Alkame Holdings, Inc. Wholly-Owned Subsidiary, High Country Shrimp Appoints Jim Keeton to the Company's Aquaculture Board of Advisors

LAS VEGAS, NV--(Marketwired - Feb 5, 2015) - Alkame Holdings, Inc. (OTCQB: ALKM) wholly owned subsidiary High Country Shrimp, LLC is pleased to announce that it has appointed Mr. Jim Keeton as an advisor to High Country's Aquaculture board of advisors. Mr. Keeton's knowledge and experience will play an integral part as we grow and develop out our aquaculture company, test center and grow facility.

"Jim's extensive industry knowledge and operational insights are going to play an important role in our success going-forward, particularly as we begin and grow into our proof of concept stage with our patented water filtration and oxygenation system within aquaculture," states Scott Hays, High Country Shrimp's President.

Mr. Jim Keeton is a consulting biologist and President and Owner of Keeton Fisheries Consultants Inc. He brings more than 40 years of experience in all aspects of development of intensive aquaculture systems in engineering, operations and design. Mr. Keeton continues to consult worldwide, and received his Degree in Fisheries Biology from Colorado State University. Jim is a Board member of the National Aquaculture Association, representing all aquaculture in the US and Canada, as well as past President of Aquaculture Suppliers Association and currently serves on the Board of Directors. He is a proven expert who has remained at the forefront of developing aquatic technology for successful fish farming and sustainable aquaculture design and manufacturing solutions.

During his career, Mr. Keeton has actively been involved in experimentation, design and manufacture of various components and equipment for aquaculture. Jim also operates a warm and cold water fish rearing facility in Fort Collins Colorado. Keeton Fisheries manufactures aeration equipment for use in various fisheries and aquaculture systems. Keeton's other work has included bioassays, field research, expert witness testimonials in the promulgation of water quality standards. Mr. Keeton is on the Board of Directors of the National Aquaculture Association, The Colorado Aquaculture Association, and a Charter member of both the National Aquaculture Association and the World Aquaculture Society.

About Alkame Holdings, Inc. (ALKM)
Alkame Holdings, Inc. is a publicly traded health and technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. Alkame uses a patented technology to create water with several unique properties which include a reduced structure that allows for better absorption, utilization, and for more efficiency, as well as help to achieve optimal pH levels. This patented technology also increases the available oxygen content which equates to more fuel for improved metabolic efficiency and boosted immune system parameters. Applications for the water treatment technology currently include consumer market products, a kids/nursery product line, pet products, and the aqua-culture industries.

For more information visit: www.alkameholdingsinc.com

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.